Corvus Pharmaceuticals
CRVS · Nasdaq · United States
Share price · CRVS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CRVS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+8.3%
- 22 Oct 2026+6.0%
Nothing announced by CRVS that day or the session before.
- 24 Sep 2026-5.9%
Nothing announced by CRVS that day or the session before.
- 22 Sep 2026+8.2%
Nothing announced by CRVS that day or the session before.
- 16 Sep 2026-5.6%
Nothing announced by CRVS that day or the session before.
- 11 Aug 2026+7.2%
Nothing announced by CRVS that day or the session before.
- 14 May 2026-13.8%
- 23 Apr 2026-10.3%
- 21 Apr 2026+10.3%
Nothing announced by CRVS that day or the session before.
- 17 Apr 2026+11.3%
Nothing announced by CRVS that day or the session before.
Share of unusual movement by asset
For each asset, the share of CRVS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | ITKSmall molecule | Atopic DermatitisNon-Hodgkin Lymphoma Peripheral T-Cell Lymphoma | |
| Phase 1/2 | adenosine A2ASmall molecule | Multiple MyelomaRenal Cell Carcinoma | |
MupadolimabNo recent activity | Phase 1 | CD73Monoclonal antibody | Non-Small Cell Lung Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
June 2027 (1)
What to watch
November 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $18M | $15M+ $188M short-term inv. | $20M-$12M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $16M | $19M+ $196M short-term inv. | $18M-$15M operating cash flow | report ↗ |
| 2026-Q1 | — | $11M | $237M | $14M | report ↗ |
| 2025-Q3 | — | $8.4M | $2.9M+ $63M short-term inv. | $10M-$9.6M operating cash flow | report ↗ |
| 2025-Q2 | — | $7.9M | $15M+ $60M short-term inv. | $8.0M-$5.8M operating cash flow | report ↗ |
| 2025-Q1 | — | $7.5M | $5.0M+ $39M short-term inv. | —-$8.3M operating cash flow | report ↗ |
| 2024-Q3 | — | $5.2M | $4.7M+ $37M short-term inv. | $40M-$6.3M operating cash flow | report ↗ |
| 2024-Q2 | — | $4.1M | $15M+ $32M short-term inv. | $4.3M-$5.5M operating cash flow | report ↗ |
| 2024-Q1 | — | $4.1M | $7.5M+ $15M short-term inv. | $5.7M-$5.2M operating cash flow | report ↗ |
| 2023-Q3 | — | $4.0M | $20M+ $12M short-term inv. | $6.0M-$5.4M operating cash flow | report ↗ |
| 2023-Q2 | — | $4.0M | $7.7M+ $29M short-term inv. | $6.5M-$5.2M operating cash flow | report ↗ |
| 2023-Q1 | — | $4.6M | $9.7M+ $25M short-term inv. | $7.9M-$8.1M operating cash flow | report ↗ |
| 2022-Q3 | — | $10M | $25M+ $25M short-term inv. | $15M-$6.9M operating cash flow | report ↗ |
| 2022-Q2 | — | $4.9M | $28M+ $28M short-term inv. | $8.4M-$6.1M operating cash flow | report ↗ |
| 2022-Q1 | — | $5.1M | $31M+ $31M short-term inv. | $8.3M-$6.4M operating cash flow | report ↗ |
| 2021-Q3 | — | $7.0M | $72M+ $4.0M short-term inv. | $11M-$8.4M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $34M | $4.6M+ $52M short-term inv. | $3.8M-$33M operating cash flow | report ↗ |
Corvus Pharmaceuticals reported no disclosed revenue for fiscal year 2025. R&D spend was $33.72M, up 73.9% YoY, with cash and equivalents of $4.58M at period end. The company recorded a net loss of $15.28M, corresponding to a quarterly net burn of $15.28M.
The company is advancing soquelitinib, its lead ITK inhibitor, in a registrational Phase 3 trial for relapsed peripheral T cell lymphoma and initiated a Phase 2 atopic dermatitis trial in March 2026, following positive cohort 4 results from the earlier atopic dermatitis study announced in January 2026. Ciforadenant continues in an open-label Phase 1b/2 trial for renal cell carcinoma in collaboration with the Kidney Cancer Research Consortium, and next-generation ITK inhibitor candidates remain in preclinical development. A follow-on public offering was completed in January 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $19M | $8.7M+ $43M short-term inv. | $16M-$25M operating cash flow | report ↗ |
| 2023-FY | — | $17M | $13M+ $14M short-term inv. | $6.8M-$24M operating cash flow | report ↗ |
| 2022-FY | — | $24M | $13M+ $29M short-term inv. | $10M-$27M operating cash flow | report ↗ |
| 2021-FY | — | $29M | $63M+ $6.0M short-term inv. | $11M-$37M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 7 purchases ($384K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | Arcara Jeffrey · Chief Business Officer | Open-market purchase | 503 | $10.37 | $5K | Form 4 |
| 2026-11-13 | Arcara Jeffrey · Chief Business Officer | Open-market purchase | 500 | $10.71 | $5K | Form 4 |
| 2026-11-12 | Arcara Jeffrey · Chief Business Officer | Open-market purchase | 497 | $11.12 | $6K | Form 4 |
| 2026-11-11 | Arcara Jeffrey · Chief Business Officer | Open-market purchase | 3,000 | $11.46 | $34K | Form 4 |
| 2026-06-11 | van den Broek Richard · director | Award / grant (derivative) | 15,000 | — | — | Form 4 |
| 2026-06-11 | Thompson Peter A. · director, 10% owner | Award / grant (derivative) | 15,000 | — | — | Form 4 |
| 2026-06-11 | Grais Linda · director | Award / grant (derivative) | 15,000 | — | — | Form 4 |
| 2026-06-11 | CLARK IAN T · director | Award / grant (derivative) | 15,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 164 reporting institutions held 70.1M shares ($979.7M, 83.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 7,165,006 | $104.8M |
| 2 | BlackRock, Inc. | 6,160,422 | $90.1M |
| 3 | STATE STREET CORP | 3,565,992 | $52.2M |
| 4 | ADAMS STREET PARTNERS LLC | 3,275,616 | $47.9M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3,234,538 | $47.3M |
| 6 | Vivo Capital, LLC | 2,805,816 | $41.0M |
| 7 | MORGAN STANLEY | 2,498,825 | $36.6M |
| 8 | Deep Track Capital, LP | 2,491,539 | $36.5M |
| 9 | WELLINGTON MANAGEMENT GROUP LLP | 2,318,517 | $33.9M |
| 10 | PERCEPTIVE ADVISORS LLC | 2,292,441 | $33.5M |
| 11 | Commodore Capital LP | 2,258,735 | $33.0M |
| 12 | Foresite Capital Management VI LLC | 1,831,233 | $26.8M |
| 13 | BRAIDWELL LP | 1,752,798 | $25.6M |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1,712,741 | $25.1M |
| 15 | MPM BIOIMPACT LLC | 1,674,875 | $24.5M |